Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone
暂无分享,去创建一个
[1] Jennifer S. Haas,et al. The impact of socioeconomic status on the intensity of ambulatory treatment and health outcomes after hospital discharge for adults with asthma , 1994, Journal of General Internal Medicine.
[2] E. R. Mcfadden,et al. Impact of race on the severity of acute episodes of asthma and adrenergic responsiveness. , 2006, American journal of respiratory and critical care medicine.
[3] L. Williams,et al. Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma , 2006, Pediatrics.
[4] P. Dorinsky,et al. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. , 2006, Clinical therapeutics.
[5] P. Dorinsky,et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.
[6] Carlos A Camargo,et al. Asthma exacerbations in North American adults: who are the "frequent fliers" in the emergency department? , 2005, Chest.
[7] E. Cook,et al. Relationship of validated psychometric tools to subsequent medical utilization for asthma. , 2005, The Journal of allergy and clinical immunology.
[8] P. Dorinsky,et al. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. , 2005, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[9] R. Pauwels,et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.
[10] M. Weatherall,et al. Systematic review of the dose-response relation of inhaled fluticasone propionate , 2004, Archives of Disease in Childhood.
[11] Susan J Wilson,et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. , 2003, The Journal of allergy and clinical immunology.
[12] P. Ind,et al. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. , 2003, Respiratory medicine.
[13] P. Dorinsky,et al. Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[14] A. Goldsobel. Inhaled Corticosteroid Reduction and Elimination in Patients with Persistent Asthma Receiving Salmeterol (SLIC) , 2002, Pediatrics.
[15] Stephen C Lazarus,et al. Banks CORTICOSTEROIDS FOR PERSISTENT ASTHMA SIGNIFICANT VARIABILITY IN RESPONSE TO INHALED Services , 2022 .
[16] P. Dorinsky,et al. Effect of fluticasone propionate/salmeterol combination product on activity induced bronchospasm in patients with persistent asthma , 2002 .
[17] J. Ford,et al. Patterns and predictors of asthma-related emergency department use in Harlem. , 2001, Chest.
[18] E. Yelin,et al. Risk factors for hospitalization among adults with asthma: the influence of sociodemographic factors and asthma severity , 2000, Respiratory research.
[19] R. Adams,et al. Factors associated with hospital admissions and repeat emergency department visits for adults with asthma , 2000, Thorax.
[20] M. Kavuru,et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. , 2000, The Journal of allergy and clinical immunology.
[21] S. Shrewsbury,et al. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA) , 2000, BMJ : British Medical Journal.
[22] W. Lumry,et al. Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of Asthma , 2000 .
[23] F. Thien,et al. An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. , 1999, American journal of respiratory and critical care medicine.
[24] P. Hessel,et al. Factors that influence emergency department visits for asthma. , 1999, Canadian respiratory journal.
[25] D. Postma,et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. , 1999, American journal of respiratory and critical care medicine.
[26] C. Camargo,et al. Prospective Multicenter Study of Relapse Following Treatment for Acute Asthma Among Adults Presenting to the Emergency Department , 1999 .
[27] C. Camargo,et al. Prospective multicenter study of relapse following treatment for acute asthma among adults presenting to the emergency department. MARC investigators. Multicenter Asthma Research Collaboration. , 1999, Chest.
[28] J. FitzGerald,et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. , 1998, The New England journal of medicine.
[29] D. Postma,et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.
[30] C. Rodrigo,et al. A new index for early prediction of hospitalization in patients with acute asthma. , 1997, The American journal of emergency medicine.
[31] A. Togias,et al. Inadequate outpatient medical therapy for patients with asthma admitted to two urban hospitals. , 1996, The American journal of medicine.
[32] R. Dales,et al. Risk factors for recurrent emergency department visits for asthma. , 1995, Thorax.
[33] B. Make,et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.
[34] P. Ind,et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.
[35] N. Pearce,et al. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. , 1992, International journal of epidemiology.
[36] Phillips Yy,et al. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.